Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab Plus CHOP for First-Line Richter's Syndrome
NCT06926205Phase 2Recruiting
- Sponsor
- GE HealthCare
- Start
- May 2024
- Primary completion
- May 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mosunetuzumab in Richter's syndrome (RS), sponsored by GE HealthCare. Primary endpoint: Efficacy of mosunetuzumab combined with CHOP (M-CHOP) after the end of induction at 6 months. Started May 2024; status: recruiting.
02
Drugs
mosunetuzumab
03
Conditions
Richter's syndrome (RS)
Beyond the preview
Go deeper on NCT06926205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06926205.